Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive supranuclear palsy: pathology and genetics.

Dennis W Dickson1, Rosa Rademakers, Michael L Hutton

  • 1Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA. dickson.dennis@mayo.edu

Brain Pathology (Zurich, Switzerland)
|May 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases.

Scientific data·2016
Same author

Genetic modification of H2AX renders mesenchymal stromal cell-derived dopamine neurons more resistant to DNA damage and subsequent apoptosis.

Cytotherapy·2016
Same author

Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.

Movement disorders : official journal of the Movement Disorder Society·2016
Same author

Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies.

Neurobiology of aging·2016
Same author

TYROBP genetic variants in early-onset Alzheimer's disease.

Neurobiology of aging·2016
Same author

[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration.

Acta neuropathologica·2016

Progressive supranuclear palsy (PSP) is a brain disorder affecting movement and cognition. Research highlights tau pathology and genetic risk factors, but a diagnostic biomarker remains elusive.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Genetics

Background:

  • Progressive supranuclear palsy (PSP) is an atypical Parkinsonian disorder.
  • Characterized by axial rigidity, vertical gaze palsy, dysarthria, and dysphagia.
  • Neuropathology reveals atrophy in the subthalamic nucleus, brainstem, and substantia nigra.

Purpose of the Study:

  • To review the neuropathological findings in PSP.
  • To discuss the genetic risk factors, particularly MAPT gene variants.
  • To explore the potential of imaging studies for diagnosis and the challenge of finding a biomarker.

Main Methods:

  • Review of neuropathological studies.
  • Analysis of genetic association studies for PSP.
  • Examination of neuroimaging research in PSP.

Related Experiment Videos

Main Results:

  • Key neuropathological findings include neuronal loss, gliosis, neurofibrillary tangles, and tau pathology in glia.
  • A common MAPT gene variant is a major genetic risk factor for sporadic PSP.
  • Imaging studies show potential for differentiating PSP, but a definitive biomarker is not yet identified.

Conclusions:

  • PSP involves distinct neuropathological changes, including tau pathology.
  • MAPT gene variants are significant risk factors, potentially affecting tau isoform expression.
  • Further research is needed to identify reliable biomarkers for early and accurate PSP diagnosis.